A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
Public ClinicalTrials.gov record NCT01501383. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy With a 24-Week Open-Label Extension
Study identification
- NCT ID
- NCT01501383
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Interventions
- VX-765 Part A Drug
- Placebo Drug
- VX-765 Part B Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2011
- Primary completion
- Jul 31, 2013
- Completion
- Not listed
- Last update posted
- Sep 29, 2020
Started 2011
United States locations
- U.S. sites
- 22
- U.S. states
- 18
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama | Northport | Alabama | — | — |
| Arizona | Phoenix | Arizona | — | — |
| Arizon | Phoenix | Arizona | — | — |
| Arkansas | Little Rock | Arkansas | — | — |
| California | Loma Linda | California | — | — |
| Florida | Bradenton | Florida | — | — |
| Florida | Wellington | Florida | — | — |
| Idaho | Boise | Idaho | — | — |
| Maryland | Baltimore | Maryland | — | — |
| Michigan | Farmington Hills | Michigan | — | — |
| Minnesota | Saint Paul | Minnesota | — | — |
| New York | New York | New York | — | — |
| New York | The Bronx | New York | — | — |
| North Carolina | Asheville | North Carolina | — | — |
| North Carolina | Charlotte | North Carolina | — | — |
| Ohio | Columbus | Ohio | — | — |
| Oklahoma | Oklahoma City | Oklahoma | — | — |
| Pennsylvania | Philadelphia | Pennsylvania | — | — |
| Texas | Dallas | Texas | — | — |
| Utah | Orem | Utah | — | — |
| Virginia | Charlottesville | Virginia | — | — |
| Washington | Renton | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01501383, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2020 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01501383 live on ClinicalTrials.gov.